Roivant Sciences Ltd. (ROIV)

$12.3

+0.11

(+0.9%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $11.99
    $12.42
    $12.30
    downward going graph

    2.52%

    Downside

    Day's Volatility :3.46%

    Upside

    0.96%

    downward going graph
  • $8.25
    $13.24
    $12.30
    downward going graph

    32.97%

    Downside

    52 Weeks Volatility :37.73%

    Upside

    7.1%

    downward going graph

Returns

PeriodRoivant Sciences Ltd.Sector (Health Care)Index (Russel 2000)
3 Months
17.48%
5.1%
0.0%
6 Months
10.31%
4.9%
0.0%
1 Year
5.13%
16.6%
0.0%
3 Years
31.55%
13.2%
-22.3%

Highlights

Market Capitalization
9.1B
Book Value
$7.35
Earnings Per Share (EPS)
5.73
PE Ratio
2.15
Wall Street Target Price
16.75
Profit Margin
2991.76%
Operating Margin TTM
-402.44%
Return On Assets TTM
-15.03%
Return On Equity TTM
127.71%
Revenue TTM
158.3M
Revenue Per Share TTM
0.2
Quarterly Revenue Growth YOY
155.0%
Gross Profit TTM
-477.1M
EBITDA
-1.0B
Diluted Eps TTM
5.73
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
4.27
EPS Estimate Next Year
-1.35
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
-0.27

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Roivant Sciences Ltd.(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
17
16
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 36.18%

Current $12.30
Target $16.75

Company Financials

FY19Y/Y Change
Revenue
2.3M
-
Net Income
-1.0B
-
Net Profit Margin
-44.8K%
-
FY20Y/Y Change
Revenue
67.7M
↑ 2812.61%
Net Income
1.2B
↓ 215.22%
Net Profit Margin
1.8K%
↑ 46608.72%
FY21Y/Y Change
Revenue
23.8M
↓ 64.85%
Net Income
-900.2M
↓ 174.99%
Net Profit Margin
-3.8K%
↓ 5556.86%
FY22Y/Y Change
Revenue
55.3M
↑ 132.34%
Net Income
-924.1M
↑ 2.65%
Net Profit Margin
-1.7K%
↑ 2111.77%
FY23Y/Y Change
Revenue
61.3M
↑ 10.84%
Net Income
-1.2B
↑ 33.1%
Net Profit Margin
-2.0K%
↓ 335.7%
FY24Y/Y Change
Revenue
124.8M
↑ 103.65%
Net Income
4.3B
↓ 453.56%
Net Profit Margin
3.5K%
↑ 5492.08%
Q1 FY23Q/Q Change
Revenue
27.4M
↑ 60.54%
Net Income
-175.4M
↓ 54.42%
Net Profit Margin
-640.79%
↑ 1616.4%
Q2 FY23Q/Q Change
Revenue
21.6M
↓ 21.01%
Net Income
-291.8M
↑ 66.35%
Net Profit Margin
-1.3K%
↓ 708.71%
Q3 FY23Q/Q Change
Revenue
37.1M
↑ 71.57%
Net Income
-304.3M
↑ 4.29%
Net Profit Margin
-820.27%
↑ 529.23%
Q4 FY23Q/Q Change
Revenue
37.1M
↑ 0.11%
Net Income
5.1B
↓ 1774.58%
Net Profit Margin
13.7K%
↑ 14541.82%
Q1 FY24Q/Q Change
Revenue
28.9M
↓ 22.11%
Net Income
-151.1M
↓ 102.97%
Net Profit Margin
-522.35%
↓ 14243.9%
Q2 FY24Q/Q Change
Revenue
55.1M
↑ 90.57%
Net Income
95.3M
↓ 163.06%
Net Profit Margin
172.85%
↑ 695.2%
FY19Y/Y Change
Total Assets
1.4B
-
Total Liabilities
450.5M
-
FY20Y/Y Change
Total Assets
2.5B
↑ 78.49%
Total Liabilities
368.4M
↓ 18.24%
FY21Y/Y Change
Total Assets
2.6B
↑ 4.55%
Total Liabilities
527.7M
↑ 43.25%
FY22Y/Y Change
Total Assets
2.6B
↓ 0.18%
Total Liabilities
546.2M
↑ 3.51%
FY23Y/Y Change
Total Assets
2.4B
↓ 7.56%
Total Liabilities
782.0M
↑ 43.18%
FY24Y/Y Change
Total Assets
7.2B
↑ 202.25%
Total Liabilities
774.0M
↓ 1.03%
Q1 FY23Q/Q Change
Total Assets
2.4B
↑ 8.47%
Total Liabilities
782.0M
↑ 0.8%
Q2 FY23Q/Q Change
Total Assets
2.1B
↓ 10.59%
Total Liabilities
802.5M
↑ 2.62%
Q3 FY23Q/Q Change
Total Assets
2.1B
↓ 3.33%
Total Liabilities
739.9M
↓ 7.8%
Q4 FY23Q/Q Change
Total Assets
7.3B
↑ 254.03%
Total Liabilities
728.1M
↓ 1.6%
Q1 FY24Q/Q Change
Total Assets
7.2B
↓ 1.23%
Total Liabilities
774.0M
↑ 6.3%
Q2 FY24Q/Q Change
Total Assets
6.5B
↓ 10.05%
Total Liabilities
601.2M
↓ 22.33%
FY19Y/Y Change
Operating Cash Flow
-1.0B
-
Investing Cash Flow
-57.6M
-
Financing Cash Flow
767.0M
-
FY20Y/Y Change
Operating Cash Flow
-761.8M
↓ 25.62%
Investing Cash Flow
1.7B
↓ 3041.94%
Financing Cash Flow
217.2M
↓ 71.69%
FY21Y/Y Change
Operating Cash Flow
-552.1M
↓ 27.52%
Investing Cash Flow
-31.7M
↓ 101.87%
Financing Cash Flow
456.3M
↑ 110.1%
FY22Y/Y Change
Operating Cash Flow
-677.7M
↑ 22.75%
Investing Cash Flow
303.3M
↓ 1056.71%
Financing Cash Flow
306.8M
↓ 32.76%
FY23Y/Y Change
Operating Cash Flow
-843.4M
↑ 24.44%
Investing Cash Flow
-44.3M
↓ 114.6%
Financing Cash Flow
499.5M
↑ 62.8%
Q1 FY23Q/Q Change
Operating Cash Flow
-179.1M
↓ 19.54%
Investing Cash Flow
113.6M
↓ 3334.21%
Financing Cash Flow
210.3M
↑ 36.14%
Q2 FY23Q/Q Change
Operating Cash Flow
-249.9M
↑ 39.56%
Investing Cash Flow
105.0K
↓ 99.91%
Financing Cash Flow
7.5M
↓ 96.45%
Q3 FY23Q/Q Change
Operating Cash Flow
-196.4M
↓ 21.41%
Investing Cash Flow
-36.5M
↓ 34815.24%
Financing Cash Flow
207.9M
↑ 2680.15%

Technicals Summary

Sell

Neutral

Buy

Roivant Sciences Ltd. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Roivant Sciences Ltd.
Roivant Sciences Ltd.
20.94%
10.31%
5.13%
31.55%
31.55%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Roivant Sciences Ltd.
Roivant Sciences Ltd.
2.15
2.15
NA
4.27
1.28
-0.15
NA
7.35
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Roivant Sciences Ltd.
Roivant Sciences Ltd.
Buy
$9.1B
31.55%
2.15
2991.76%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Roivant Sciences Ltd.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 28.93M → 55.13M (in $), with an average increase of 47.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -151.11M → 95.29M (in $), with an average increase of 258.6% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 32.0%

Institutional Holdings

  • SB INVESTMENT ADVISERS (UK) LTD

    9.65%

  • Viking Global Investors LP

    9.35%

  • Qvt Financial LP

    9.02%

  • FMR Inc

    6.29%

  • Morgan Stanley - Brokerage Accounts

    4.82%

  • BlackRock Inc

    4.78%

Company Information

roivant is a global healthcare company focused on rapidly developing innovative medicines. we believe that the key to unlocking innovation in drug discovery and drug commercialization is to reduce the time and cost of the drug development process. we solve this problem by building vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in pharma r&d; and commercialization. the goal of our model is to ensure that important medicines rapidly reach patients who suffer from serious diseases. we focus on disease areas where the magnitude of r&d; investment from industry is disproportionately low relative to societal medical needs. we also launch new vants to directly improve the process of developing and commercializing new medicines. our pipeline spans multiple therapeutic areas through partnerships with academic institutions and biopharmaceutical companies, including tak

Organization
Roivant Sciences Ltd.
Employees
908
CEO
Mr. Matthew Gline
Industry
Financial

Discover More

FAQs